Guyasuta Investment Advisors Inc. boosted its stake in Allergan PLC. (NYSE:AGN) by 43.0% during the first quarter, Holdings Channel reports. The institutional investor owned 77,819 shares of the company’s stock after buying an additional 23,382 shares during the period. Allergan PLC. accounts for about 2.2% of Guyasuta Investment Advisors Inc.’s portfolio, making the stock its 21st largest position. Guyasuta Investment Advisors Inc.’s holdings in Allergan PLC. were worth $18,593,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. RidgeWorth Capital Management LLC boosted its stake in shares of Allergan PLC. by 8,828.5% in the first quarter. RidgeWorth Capital Management LLC now owns 55,178 shares of the company’s stock worth $13,183,000 after buying an additional 54,560 shares during the period. Todd Asset Management LLC boosted its stake in shares of Allergan PLC. by 215.7% in the first quarter. Todd Asset Management LLC now owns 112,223 shares of the company’s stock worth $26,812,000 after buying an additional 76,673 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of Allergan PLC. by 15.4% in the first quarter. Great Lakes Advisors LLC now owns 17,976 shares of the company’s stock worth $4,295,000 after buying an additional 2,395 shares during the period. Clifford Swan Investment Counsel LLC boosted its stake in shares of Allergan PLC. by 10.1% in the first quarter. Clifford Swan Investment Counsel LLC now owns 33,970 shares of the company’s stock worth $8,116,000 after buying an additional 3,121 shares during the period. Finally, Oxford Asset Management boosted its stake in shares of Allergan PLC. by 282.2% in the first quarter. Oxford Asset Management now owns 12,414 shares of the company’s stock worth $2,966,000 after buying an additional 9,166 shares during the period. 84.63% of the stock is owned by hedge funds and other institutional investors.
Allergan PLC. (AGN) opened at 248.91 on Tuesday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $261.27. The firm has a market cap of $83.60 billion, a P/E ratio of 7.76 and a beta of 1.16. The firm’s 50-day moving average price is $230.38 and its 200-day moving average price is $227.81.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Tuesday, May 9th. The company reported $3.35 EPS for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.03. The business had revenue of $3.57 billion during the quarter, compared to analyst estimates of $3.53 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.04 EPS. Equities research analysts expect that Allergan PLC. will post $16.08 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th were paid a $0.70 dividend. The ex-dividend date of this dividend was Tuesday, May 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.12%. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.63%.
A number of analysts have recently commented on the company. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target for the company in a research note on Monday. BidaskClub raised Allergan PLC. from a “sell” rating to a “hold” rating in a research note on Saturday, June 17th. ValuEngine cut Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald assumed coverage on Allergan PLC. in a research note on Friday, June 16th. They issued a “neutral” rating and a $231.00 price target for the company. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and issued a $279.00 price target on shares of Allergan PLC. in a research note on Tuesday, March 14th. Eight investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $271.38.
In related news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/guyasuta-investment-advisors-inc-acquires-23382-shares-of-allergan-plc-agn/1942344.html
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.